Insulet Corporation (PODD) is forecasted to report earnings per share (EPS) of approximately $0.81 for Q1 2025, compared to the previous quarter's EPS of $1.151. This indicates a decline in earnings, which could be due to increased expenses, such as a 22.6% rise in selling, general & administrative expenses and a 44.3% rise in research and development costs1. The estimated revenue for Q1 2025 is $542.81 million, reflecting a 17-21% increase in Omnipod revenue growth forecast1. However, this is overshadowed by a projected 45%-55% decline in Drug Delivery revenue for 20251. Insulet's competitors, such as Tandem Diabetes Care (TNDM), are also expected to report negative EPS of approximately -$0.6 for the same period, with an estimated revenue of $220.16 million2. It's important to note that these forecasts are based on current market conditions and may be subject to change.